What is the best medication for premenstrual dysphoric disorder in a typical reproductive‑age woman without contraindications to serotonergic agents?

Best Medication for PMDD

SSRIs (selective serotonin reuptake inhibitors) are the best medication for premenstrual dysphoric disorder, with fluoxetine and paroxetine being FDA-approved specifically for this indication and demonstrating the strongest evidence for efficacy. 1, 2

First-Line Treatment: SSRIs

SSRIs probably reduce overall premenstrual symptoms substantially (SMD -0.57) and are considered the gold-standard first-line treatment for PMDD 2, 3, 4, 5. The evidence supports:

Specific SSRI Options (in order of evidence strength):

• Fluoxetine - FDA-approved for PMDD 1
• Paroxetine - FDA-approved for PMDD, particularly effective 1, 4
• Sertraline - Well-studied alternative 2
• Escitalopram and citalopram - Additional options 2

Dosing Strategy

Continuous dosing is more effective than luteal-phase-only dosing (SMD -0.69 vs -0.39, P=0.03), though both approaches work 2. This represents a unique aspect of PMDD treatment—unlike typical depression, SSRIs can be effective when administered only during the luteal phase (2 weeks before menses), though continuous administration yields superior results 6.

Practical approach:

• Start with continuous daily dosing for maximum efficacy
• Consider luteal-phase dosing (days 14-28 of cycle) if patient prefers intermittent treatment or experiences side effects with continuous use
• Symptom-onset dosing is another option but requires more research 5

Second-Line Treatment: Hormonal Contraception

For women who also desire contraception or fail SSRI therapy, oral contraceptives containing drospirenone (a progestin with antimineralocorticoid activity) have FDA approval for PMDD treatment 6. This represents the only hormonal contraceptive with specific PMDD indication.

Expected Adverse Effects of SSRIs

Patients should be counseled about common side effects (all moderate-certainty evidence) 2:

• Most common: Nausea (OR 3.30), asthenia/decreased energy (OR 3.28), somnolence/decreased concentration (OR 3.26)
• Sexual: Decreased libido/sexual dysfunction (OR 2.32)
• Neurological: Tremor (OR 5.38), dizziness (OR 1.96)
• Other: Dry mouth (OR 2.70), sweating (OR 2.17), diarrhea (OR 2.06), insomnia (OR 1.99)

Important Clinical Caveats

Drug interactions matter: Fluoxetine and paroxetine are strong CYP2D6 inhibitors. If patients are taking tamoxifen (for breast cancer), avoid paroxetine and fluoxetine as they decrease formation of active tamoxifen metabolites; use alternatives like citalopram or venlafaxine instead 7, 1.

Diagnosis requires prospective tracking: Before initiating treatment, confirm diagnosis with prospective daily symptom tracking across at least two menstrual cycles to document luteal-phase-specific symptoms 8. Single retrospective reports are insufficient.

Black box warning: SSRIs carry warnings for treatment-emergent suicidality, particularly in adolescents and young adults 1.

Alternative Options if SSRIs Fail or Are Contraindicated

1. SNRIs: Venlafaxine and duloxetine show efficacy 5
2. Anxiolytics: Alprazolam or buspirone 5
3. Ovulation suppression: GnRH agonists with add-back therapy for severe refractory cases 9
4. Calcium supplementation: 1200mg daily has demonstrated consistent benefit 5
5. Cognitive-behavioral therapy: Evidence-based non-pharmacological option 3

The treatment hierarchy is clear: start with SSRIs (preferably fluoxetine or paroxetine) using continuous dosing, counsel about expected side effects, and reserve hormonal or other interventions for SSRI failures or when contraception is simultaneously desired.